EU Launches 3-Day Health and Pharma Investment Mission in Guyana
June 2 2025- The European Union’s Global Gateway Health and Pharma Investment Mission officially commenced on Monday at the Marriott Hotel in Kingston, Georgetown, bringing together nearly 10 health and pharmaceutical companies from seven EU member states.
Running from June 2 to 4, the three-day mission is part of the EU’s broader Global Gateway initiative, which aims to promote sustainable investment and strengthen partnerships with key regions across the world. This week’s focus is on Guyana’s rapidly developing healthcare and pharmaceutical sectors.
During the opening ceremony, Minister of Health Dr. Frank Anthony highlighted the significance of the initiative, noting the substantial growth and development within Guyana’s healthcare system.
He welcomed the collaboration and emphasized the importance of international partnerships in advancing national health objectives.
Minister Anthony highlighted Guyana’s growing capacity to provide healthcare services to individuals from outside the country.
Organised by the EU Delegation in Guyana, the mission provides a platform for European companies to engage directly with Guyanese stakeholders. Participants will explore opportunities for collaboration, gain insights into regulatory frameworks, examine market trends, and assess potential for investment in the country’s expanding health infrastructure.
The programme features a series of seminars, one-on-one business meetings, and field visits, aimed at fostering partnerships and encouraging investment in what is emerging as a vibrant and dynamic market.
The investment mission also follows recent high-level EU-Caribbean engagement. At the CARICOM Heads of Government Conference in February, European Commission President Ursula von der Leyen announced a new initiative to support pharmaceutical manufacturing in Barbados and Guyana. The programme includes components such as regulatory cooperation, investment facilitation, and educational exchanges, with the goal of building resilient and independent pharmaceutical value chains in the Caribbean. (Newsroom photo)
